Skip to main content
. Author manuscript; available in PMC: 2015 Feb 3.
Published in final edited form as: Dig Dis Sci. 2014 May 3;59(6):1222–1230. doi: 10.1007/s10620-014-3186-3

Table 2.

Baseline analysis. Endoscopic surveillance is performed in both scenarios, and proton pump inhibitors are assumed to reduce the risk of esophageal adenocarcinoma by 50 %

Strategy Cost
($)		 Effectiveness
(dQALY)		 Incremental
cost ($)		 Incremental
effectiveness (dQALY)		 ICER
($/dQALY)		 Cancers
per 100 NDBE
No chemoprevention 19,789 19.02 0 0 0 5.6
PPIs 23,495 19.33 3,706 0.32 11,760 2.3